RE:RE:RE:Nothing but up from here folks!!
from Feb 25, 2021 MD&A
(3) The Companys discovery and formulation development programs includes exploring novel uses of Bucillamine for infectious diseases, liver diseases, and other psychedelic compounds for various disorders in pre-clinical models. The Company is pursuing the development of a next generation formulation of Bucillamine. The $2,000,000 is anticipated to be allocated to cover the following milestones and activities for the discovery research and formulation development: (i) complete pre- clinical research of Bucillamine in various in-vitro and in-vivo models targeting infectious diseases and respiratory disorders under a research agreement with academic research laboratories or clinical research organizations ($500,000); (ii) complete pre-clinical research with DMT, MDMA and LSD in various in-vitro and in-vivo models targeting various neurological disorders under a research agreement with academic research laboratories or clinical research organizations ($500,000) and (iii) conduct reformulation development program with Bucillamine with the aim to improve the oral bioavailability and generate new intellectual property ($1,000,000).